Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

N-912

Supelco

Norbuprenorphine solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H35NO4
CAS Number:
78715-23-8
Molecular Weight:
413.55
EC Number:
200-659-6
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

100 μg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4)c56

InChI

1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1

InChI key

YOYLLRBMGQRFTN-IOMBULRVSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Norbuprenorphine is the primary active metabolite of the opiate buprenorphine in urine. This Certified Spiking Solution® is suitable as a starting material for use as calibrators and controls in GC/MS and LC/MS methods in forensic analysis, clinical toxicology, urine drug testing, or pain prescription monitoring. Buprenorphine, sold under trade names such as Buprenex®, Subutex® and Suboxone®, is an opiate drug used to treat opioid addiction and to moderate acute pain.

Application

  • Norbuprenorphine solution for opioid receptor research: A study analyzed the pharmacokinetics of buprenorphine and its metabolite norbuprenorphine in neutered male cats anesthetized with isoflurane, highlighting its role in opioid receptor agonist research and the impact on pain management strategies (Pypendop et al., 2023).
  • Metabolite solution for biochemistry experiments: A study addressed the quantitative analysis of buprenorphine and norbuprenorphine levels in urine, demonstrating norbuprenorphine′s application in biochemistry experiments to understand opioid use disorder and its treatment (Holt et al., 2018).

Legal Information

Buprenex is a registered trademark of Reckitt & Colman (Overseas) Ltd
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited

related product

Product No.
Description
Pricing

B-035

Buprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-044

Buprenorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-901

Buprenorphine-D4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-902

Buprenorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-908

Buprenorphine-D4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

N-045

Norbuprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-059

Norbuprenorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-920

Norbuprenorphine-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-921

Norbuprenorphine-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-100

Buprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-101

Buprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-145

Norbuprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-146

Norbuprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

WGK

WGK 1

Flash Point(F)

closed cup

Flash Point(C)

closed cup

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jinda Fan et al.
Bioconjugate chemistry, 22(4), 752-758 (2011-03-26)
Norbuprenorphine-3-β-d-glucuronide (nBPN-3-β-d-G, 1) is a major phase II metabolite of buprenorphine, a pharmaceutical used for the treatment of opioid addiction. The pharmacological activity of compound 1 is not clear because investigations have been limited by the lack of chemically pure
Panagiota Nikolaou et al.
Biomedical chromatography : BMC, 26(3), 358-362 (2011-07-02)
Buprenorphine (BUP) is used for the maintenance of opioid-addicted pregnant women. Because BUP and its main metabolite nor-BUP are excreted into breast milk, a sensitive and specific GC/MS method has been developed, optimized and validated for their determination in breast
Xia Luo et al.
Antimicrobial agents and chemotherapy, 56(7), 3641-3647 (2012-05-09)
This was an open-label, single-sequence trial in hepatitis C virus-negative volunteers on stable, individualized, buprenorphine maintenance therapy. Telaprevir at 750 mg every 8 h was coadministered with buprenorphine/naloxone (4:1 ratio as sublingual tablets) for 7 days with food. Pharmacokinetic profiles
Kenneth F Ilett et al.
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 7, 269-274 (2011-10-21)
The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4-24 mg)
Kristen M Messenger et al.
Veterinary anaesthesia and analgesia, 38(4), 374-384 (2011-04-20)
To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration. Randomized crossover experiment; prospective study. Eleven healthy adult horses between
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service